文献速递白血病

干扰素在毛细胞白血病中的当前作用:临床与分子层面

The current role of interferon in hairy cell leukaemia: clinical and molecular aspects.
PubMed 文献 · Br J Haematol · 2021-05-01

该回顾性分析纳入74例毛细胞白血病患者,分三组:A组>65岁初治、B组有合并症初治、C组嘌呤类似物耐药。总缓解率94%,完全缓解率24%;中位随访60个月,55例(78%)仍持续缓解。A、B、C组5年无进展生存率分别为95%、68%、96%。部分患者监测BRAF-V600E状态,干扰素α仍是特定患者的可选方案。

要点

  • 干扰素α在特定毛细胞白血病患者中仍为可选治疗。
  • 总缓解率94%,完全缓解率24%。
  • 中位随访60个月,78%患者持续缓解。

核心结论

  • 干扰素α仍是特定毛细胞白血病患者的可能选择,可实现微小残留病阴性。

研究设计与样本

  • 回顾性分析74例毛细胞白血病患者,分为三组:A组>65岁初治、B组有合并症初治、C组嘌呤类似物耐药。

主要发现

  • 总缓解率94%,完全缓解率24%。
  • 中位随访60(7-236)个月,55例(78%)仍持续缓解。
  • 5年无进展生存率:A组95%、B组68%、C组96%。
  • 部分患者监测BRAF-V600E状态。

临床怎么用

  • 对特定毛细胞白血病患者(如>65岁、有合并症或嘌呤类似物耐药)可考虑干扰素α治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We investigated the current role of interferon-alpha (IFNα) in hairy cell leukaemia (HCL) in a retrospective analysis of patients with HCL. A cohort of 74 patients with HCL was divided in to three groups: (A) patients aged >65 years with first-line treatment; (B) patients with comorbidities with first-line treatment; (C) patients who were purine analogues resistant. In total, 94% achieved a response, with a complete response rate of 24%. After a median (range) follow-up of 60 (7-236) months, 55 patients (78%) are still responding. The 5-year progression-free survival was 95%, 68%, and 96% in groups A, B and C respectively. A proportion of patients were monitored through their B-Raf proto-oncogene, serine/threonine kinase (BRAF)-V600E status. IFNα remains a possible option in select patients with HCL, where minimal residual disease negativity is achievable.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Assanto GM, Riemma C, Malaspina F, et al. The current role of interferon in hairy cell leukaemia: clinical and molecular aspects. Br J Haematol. 2021. PMID: 33932027. doi:10.1111/bjh.17440

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。